m-RESIST Newsletter Issue 1 | February 2016
Email not dislpaying correctly? View it in your browser.


Dear readers,

We are very glad to introduce you the first newsletter of the m-RESIST project.
m-RESIST is a 36-months EU co-funded project under the Horizon 2020 research and innovation framework program. This European Project aims to develop a therapeutic program that provides medical, cognitive and psychosocial tools that draws on the support of mobile devices. We consider this m-Health approach will help to actively involve patients with treatment-resistant schizophrenia and their carers, as well as to make them more capable of self-managing their own illness.
Launched in January 2015, m-RESIST is expected to implement a model of analysis, in order to move forward in understanding treatment - resistant schizophrenia.
Project activities will help predicting patient’s behaviour and will allow the establishment of a reaction alert system, as well as to draw up protocols and recommendations to give clinicians support in their medical decisions. By linking data mining tools with a high-level predictive model, m-RESIST will bring forth a new technical focus for health treatments. This will allow the behaviour patterns found in many patients’ data to be analysed in order to identify the risks and shortcomings of the treatments.
In this first issue of our newsletter, you will have the opportunity to read our project news, upcoming and past events.

Thank you for your interest in our work! Enjoy the reading!
The m-RESIST consortium

Project News

m-RESIST group  has performed a  qualitative study to identify the user’s needs

At the end of May 2015, users’ focus groups were performed in the three countries involved (Spain, Hungary and Israel).
This activity was led by Parc Sanitari Sant Joan de Déu (Spain) with the support and collaboration of Gertner Institute (Israel) and Semmelweis University (Hungary).
This was a qualitative study on treatment-resistant schizophrenia outpatients’ needs performed before defining the system requirements.
As a result, the project obtained the opinions and suggestions on the m-RESIST solution from 3 groups of users: patients, clinicians and informal carers.


The three clinical partners of the m-RESIST group have been working on a document to identify and compare available health care resources in Israel, Hungary and Spain

During the first 6 months of the project, one of the m-RESIST activities performed was to describe the available health care resources and pathways of care for the most common problems of treatment-resistant schizophrenia, and how it was anticipated that the m-RESIST service would be provided.
The output of this activity was documented in “m-RESIST services and care pathways” report. This contained a detailed description of the current services available in each of the 3 countries were pilots will be developed, and the new or improved care services to be delivered.


Exploring sensors for monitoring patients with treatment-resistant schizophrenia

Several sensors are currently available with smart watches, bracelets, smartphones and technology devices in general. During this year, m-RESIST explored all the possible solutions that could be used for friendly monitoring patients with treatment-resistant schizophrenia. These solutions may support the acquisition of implicit parameters, without interfering in patient's daily life, though providing an estimation of the physiological and mental state.
We are setting up the use of a smart watch, to acquire physiological information, and the use of ad-hoc mobile application on the patient’s smartphone, to quantitatively depict the lifestyle of the user in terms of movement activity, motion habits, and social activity



Lifespan Development of Schizophrenia and How the Treatments Improve Outcome

“According to a systematic literature review including 260 studies, treatment-resistant schizophrenia is a poorly studied and understood condition contrasted to its high prevalence, clinical importance and severity. There is lack of studies on epidemiology, for example risk factors, as well as outcomes and longitudinal course of this disorder”
(Seppälä et al. What do we know about Treatment-Resistant Schizophrenia? - A Systematic Review. Conference abstract to be presented in 24th European Congress of Psychiatry, Madrid, Spain, 12-15 March 2016).

Despite what is known, the aforementioned topics evidence the existence of significant gaps in the scientific knowledge and clinical practice related to treatment-resistant schizophrenia. In fact most of the earlier studies on this condition concern medication. However, the quality of trials and the evidence base for the treatment recommendations remain poor (Molins. Response to antipsychotic drugs and ECT in treatment-resistant schizophrenia and clozapine-resistant schizophrenia: a systematic review. 2016). During the next years, m-RESIST will aim to provide tools that help to deepen on the illness.

m-RESIST at RRI & SSH in ICT-related projects of H2020 - Getting started! Workshop

m-RESIST was identified by DG CONNECT as a project with a significant societal dimension, that requires a proper attention to SSH (social sciences and humanities) expertise and RRI (responsible research and innovation) actions, such as public engagement, gender equality, and ethical issues. It was invited to the workshop “RRI and SSH in ICT-related projects of H2020 - Getting started”,  co-organised by European Commission’s DG Connect and the RRI-ICT Forum project, which took place in Brussels on July 8-9, 2015. The RRI-ICT Forum is a H2020 coordination and support action launched on last January 1st for a period of 3 years, with the main objective to bring to life the responsible approach to research and innovation in the ICT-related projects of H2020. This includes curating the RRI-ICT domain in H2020, facilitating community views and agenda, and empowering other projects and the European Comission.

m-RESIST website: the online informational tool of the project

The website of the m-RESIST project serves as the major dissemination and communication tool that includes the entire project related information as well as interesting news.
You can have a look at it here!

m-RESIST promotional material

m-RESIST created its first promotional material that presents and provides information about the project.

Did you know that?

m-RESIST has been presented in the following events, succeeding in raising the awareness of the project to its relevant stakeholders.
In addition m-RESIST Poster “What do we know about treatment resistant schizophrenia? - A systematic review” has been presented by BSc, med. student Annika Seppälä (Finland) at the 13th Science Day of the Campus of Kontinkangas of the University of Oulu on 23 February 2016 and has won an award for the best poster presentation.

Where to look next!

1. m-RESIST will be presented during the Symposium “Lifespan development of schizophrenia and how the treatments improve outcome”, chaired by Professor emeritus Matti Isohanni (Finland) during the European Congress of Psychiatry (EPA 2016), that will be held on 12 – 15 March 2016, in Madrid, Spain. During the symposium the following presentations will take place:
  • “Treatment-resistant schizophrenia during life span: epidemiology, outcomes and innovative m-Health treatments within m-RESIST project” by MA Katya Rubinstein (Israel).
  • “Somatic comorbidity and its outcomes in schizophrenia during lifespan” by MD, PhD Jussi Seppälä (Finland).
  • E-poster presentation “What do we know about treatment resistant schizophrenia? - A systematic review”, by BSc, med. student Annika Seppälä (Finland).
2. m-RESIST Poster “m-RESIST, an Integrative M-Health Solution for Treatment-Resistant Schizophrenia According to User’ needs: Focus Groups Findings” will be presented by PhD  Elena Huerta-Ramos (Spain) at the 5th Biennial Schizophrenia International Research Society Conference (SIRS 2016) that will be held on 2-6 April, 2016 in Florence, Italy.  

3. m-RESIST Oral presentation “Somatic Comorbidity and its Outcomes in Schizophrenia during Lifespan” will be presented by MD, PhD Jussi Seppälä (Finland) at SIRS 2016 as well.

4. m-RESIST Oral Poster,  “An innovative and integrative m-Health solution for treatment resistant schizophrenia patients” will be presented by MSc Anna Alonso (Spain) on  25 May 2016 at  the 16th International Conference on Integrated Care (ICIC16) that will be held in Barcelona, Spain. 

Who are we?

Contact information
Project coordinator
Margarita Hospedales Salomo, FUNDACIO TICSALUT (Spain)


Do you want to be part of it or know about it?

Copyright © 2016 m-RESIST - All rights reserved.

This project is co-funded by the Horizon 2020 Framework Programme of the European Union under grant agreement no [643552].

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.